A new algorithm and web server, mutation3D (http://mutation3d.org), proposes driver genes in cancer by identifying clusters of amino acid substitutions within tertiary protein structures.
Introduction
either in part or in full. For any given protein, many overlapping models may be available from either or both sources. mutation3D will invariably use entries from the PDB when they are available, as these experimentally determined crystal structures are considered to be a 'gold standard' in structural biology. To increase structural coverage of the proteome, the user may also select a subset of homology-based models to include, based upon several This article is protected by copyright. All rights reserved. 6 quality metrics available via the Advanced Query page (Supp. Note S2). Once a set of PDB structures and structural models has been established for a single protein, mutation3D
attempts to cluster amino acid substitutions on all models separately, and reports any model or experimentally determined structure in which a cluster has been found. In our analyses we consider it sufficient to implicate a protein in cancer if any of its models are found to contain a cluster.
Some whole proteins or regions of proteins may not have been crystallized or modeled todate. Owing to the lack of structural coordinates in these regions, we would be unable to identify clusters of mutations. There are some cases in which a single genomic mutation may
give rise to defects in distinct proteins, in which case mutation3D will attempt to find clusters across all proteins and models for which this mutation has an effect on protein products.
Users may elect to set the CL-distance, or the maximum allowable distance between α-carbons in a cluster of substituted amino acids. We refer to this as the maximum cluster diameter as this is equivalent to the maximum allowable diameter in Angstroms of a sphere encapsulating all α-carbons in a cluster. With regard to the complete linkage clustering algorithm, the CL-distance is the maximal dissimilarity between elements, after which, no new merging of elements and groups of elements occurs. In mutation3D, we call this parameter the Maximum Clustering Diameter, which is measured in Angstroms, and represents the maximum distance between amino acid substitutions after which no further merging of single mutations with clusters occurs and clusters are assigned based on current hierarchical groupings of mutations. For more information on all algorithm parameters and their default values, see Supp. Notes S2 and S3.
Statistical significance of clusters
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In order to calculate the statistical significance of clusters found by complete-linkage clustering, mutation3D performs an iterative bootstrapping method to calculate a background distribution of cluster sizes arising from a random placement of an equivalent number of substitutions in a given protein structure. By default, mutation3D will randomly rearrange all amino acid substitutions 15,000 times in a given structure and calculate the minimum CLdistance at which a cluster of size n (where n is all cluster sizes found in the original data) is observed in the randomized data. For each cluster in the original data, P-values are computed empirically as the percentile rank of its CL-distance among all CL-distances for randomized clusters containing the same number of amino acid substitutions. The clustering algorithm/statistical significance calculator is implemented in C++ and is available for download as a command-line tool.
There is precedent, even within cancer gene detection, for the use of iterative bootstrapping methods when the background distributions are unclear or complicated (Hodis, et al., 2012; Lawrence, et al., 2014) . Here we use bootstrapping to account for vastly different configurations of the protein backbone in different protein structures.
Compiling a protein structure and model set
In order to build a repository of protein structures and models, we curated experimentallydetermined crystal structures from the PDB and homology models from ModBase by searching for canonical isoforms of Swiss-Prot structures or chains in both. Since many PDB structures provide too little coverage of their target protein to be useful for clustering, we retained only those structures that cover at least 250 amino acids or 40% of their target protein. We only retained ModBase models that have an MPQS score ≥ 0.5, and maintain a default cutoff of MPQS ≥ 1.1 in the mutation3D interface and in our analyses. All structures and models were compared against each other to remove redundancies (i.e. a ModBase model
This article is protected by copyright. All rights reserved. 8 that is of higher quality than and whose range of amino acids is entirely contained within a second ModBase model derived from the same PDB structure was considered not to add any novel structural information to our repository). Furthermore, the amino acid indices of all models and structures were realigned using SIFTS (Velankar, et al., 2013) to match the amino acid indices of the Swiss-Prot protein they represent.
mutation3D web interface
To build the mutation3D web interface, we leveraged the power and flexibility of several well known JavaScript packages, such as JQuery and Bootstrap, in addition to a package designed to draw static two-dimensional figures (KineticJS). The cornerstone of our display system is an entirely JavaScript-based molecular viewer, GLmol, which allows users to view interactive 3D protein structures natively in modern web browsers supporting the new WebGL standard, without downloading any additional software. We have made modifications to these software packages to allow triggering of events by the user, such as highlighting mutations and mutation clusters simultaneously in the 3D and 2D
representations of proteins.
To speed up web accession for both single and batch queries, mutation3D runs on a multicore web server and the calculation of clusters is distributed among available computing cores using multithreaded CGI programs.
Compiling mutations and variants affecting aromatase
We compiled a list of all inherited missense mutations from the Human Gene Mutation
Database . Table S2 ). Please note that nucleotides are indexed in coding sequences, using the A of the ATG translation initiation start site as nucleotide 1. Visual inspection was performed by highlighting C α positions in aromatase (PDB: 3S79) using PyMol (Schrodinger, 2010) .
Segregating disease mutations from SNPs
For each Swiss-Prot protein from UniProt, a set of pathogenic inherited mutations from HGMD was assembled for the catalogued disease with the greatest number of associated mutations in that protein. Proteins with fewer than three pathogenic mutations (two of which were required to occur at unique amino acid positions) associated with any one disease were not considered as this is the minimum requirement for identifying a cluster with default mutation3D parameters (Supp. Notes S2 and S3). Separately, we assembled non-synonymous SNPs (nsSNPs) with MAF ≥ 1% from the ESP 6500 set, only retaining proteins if there were at least three SNPs in the protein, two of which caused amino acid substitutions at unique amino acid positions. We intersected these two sets and only retained proteins that occurred in both sets as meeting the individual criteria of three mutations from each set, two of which must have been at unique amino acid positions, for a total of six or more variants per protein. In total, we retained 8,869 inherited diseaseassociated mutations from HGMD and 2,004 nsSNPs from ESP 6500 in 336 proteins.
We used mutation3D to identify clusters in the resulting proteins, employing a fairly strict definition of a cluster whereby a cluster was identified if three or more substitutions were found within the complete linkage clustering distance of 15 Å, with at least two substitutions occurring at unique amino acid locations. 3D model sets were derived from PDB structures This article is protected by copyright. All rights reserved. 10
and ModBase models indicated to be of high quality by an MPQS ≥ 1.1 (full details on default parameters for mutation3D are available in Supp. Notes S2 and S3). We report the average per-protein clustering rates across all proteins for which models from the correct set were available. P-values were calculated using a U test.
Measuring the overlap between mutation3D-implicated genes and the Cancer Gene Census
To assess whether mutation3D is able to report known cancer genes, we ran mutation3D with default parameters (Supp. Notes S2 and S3) on all WGS screens in COSMIC v75 (285 studies). We varied the maximum cluster diameter from 5 Å to 25 Å and identified the fraction of proteins implicated (as having one or more clusters of amino acid substitutions)
that are known cancer genes. We define known cancer genes to be the union of genes included in the Cancer Gene Census (Futreal, et al., 2004) and MutSig drivers list (Lawrence, et al., 2014) . Overlaps between mutation3D-identified genes and known cancer genes were computed as the number of known cancer genes identified by mutation3D divided by the total number of genes implicated by mutation3D in each tissue category and overall (this is also known as the precision or positive predictive value (PPV)):
PPV = TP / ( TP + FP )
where TP is the number of true positives and FP is the number of false positives predicted by mutation3D. It should be noted that since the our set of known cancer genes is far from complete, this estimation is likely to represent the lower bound of the true precision of our method. Furthermore, we acknowledge that even genes in the set of known cancer genes may not be drivers in all cancer types. However, the overlap between our results and the known cancer genes is likely to correlate with the underlying precision of our method and there is no reason to believe that the overlap will be biased in certain cancer types. Therefore, this measurement can be used to estimate the lower bound of the precision of our method in comparing its performance across different cancer types. Calculation of sensitivity and specificity is inappropriate in this instance because no method could re-capitulate all known cancer genes as no data set (single WGS study or a group of WGS) can be assumed to harbor all mechanisms underlying tumorigenesis. We also computed the overlap of all genes in these 285 COSMIC studies with known cancer genes for each tissue category and across all tissues, to show that performing 3D clustering at any maximum cluster diameter increases precision over random expectation for this data set. P-values were calculated using a Z test to compare each fraction of identified genes by clustering at different diameter thresholds to the fraction of identified genes without clustering.
Assessing the likelihood of mutations clustered with mutation3D to be causal
In addition to predicting driver genes based on those found to contain clusters, mutation3D
has the ability to predict those mutations likely to drive cancer phenotypes by their inclusion in clusters. Here, we used two proxies for causal driver mutations: that they should be more likely to be damaging and they should be more frequently observed in WGS studies.
We determined PolyPhen-2 scores (using the HumVar-trained model for assigning categories) of those mutations likely to be most deleterious biochemically based on a
Grantham score (Grantham, 1974) in the top 25%. This shows how a combined biochemical and evolutionary genetics approach could lead to the discovery of new driver mutations.
PolyPhen-2 scores were accessed using the Ensembl Variant Effect Predictor, assembly
GRCh38.p5 (http://www.ensembl.org/Tools/VEP) (McLaren, et al., 2010) .
(CYP19A1) gene leading to amino acid substitutions at 8 positions along the aromatase protein backbone (Supp. Table S1 ). The Exome Sequencing Project (ESP) 6500 data set (Fu, et al., 2013) contains two common non-synonymous SNPs (nsSNPs) with MAF ≥ 1% in this gene, which we consider likely to be benign given their high frequency of occurrence (Supp. Table S2 ). Based on the primary sequence alone, no clear pattern or separation can be detected between the disease mutations and nsSNPs ( Figure 1a) . However, when we inspect the locations of these two classes of mutation on an experimentally-determined crystal structure of aromatase (PDB: 3S79 in Figure 1a) , it is evident that the verified disease mutations and common nsSNPs are localized in quite different regions of the protein, suggesting somewhat different functional consequences depending upon the location of a mutation within the tertiary structure of the protein.
Commonly observed cancer mutations form a tight cluster in GTPase KRas
Cancer mutations may also aggregate within clusters in protein structures, and this aggregation is likely to have profound implications for our ability to differentiate functional driver mutations from neutral passenger mutations. Consider the canonical oncogenic protein
GTPase KRas: the tight clustering of commonly mutated amino acid substitutions in codons 12, 13 and 61 suggests that these mutations cause similar structural perturbations that may lead to many types of cancer (Figure 1b) . In fact, it has long been known that substitutions in these codons confer tumorigenesis, and several mechanisms have been proposed (PylayevaGupta, et al., 2011) (Supp. Note S4, Supp. Table S3 ). Interestingly, another amino acid substitution E49K has only been reported once in a single patient (Guedes, et al., 2013) and is predicted to be benign by PolyPhen-2 (Adzhubei, et al., 2010) . The clear spatial separation of the known driver mutations from the putatively benign mutation indicates a highly specific correlation between protein structure and function in cancer. Owing to its very high mutation frequency in many different types of cancer, KRAS [MIM# 190070 ] is readily identifiable as tumorigenic by many methods; however, mutation3D is uniquely positioned to be able to detect similar cases of spatially specific disruption in proteins currently unknown for their This article is protected by copyright. All rights reserved. 14 roles in tumorigenesis by relating cancer sequencing data to aberrations in the structural proteome.
Coordinating mutations and structural data into a tool for whole-genome inference mutation3D identifies mutations that group together to form statistically significant clusters on the folded protein backbone based on atomic coordinates derived from experimentally determined crystal structures and homology models. Cluster significance is measured by an iterative bootstrapping model, in which observed mutations are randomly rearranged on a protein structure, and the size of the observed cluster is ranked compared to all randomly derived clusters to compute an empirical P-value (see Methods for details). The accompanying web interface provides visualization of these clusters as well as the ability to rapidly switch views between all available structures. Figure 2 describes the curation of structural and mutation data, and user accession and download procedures.
Structural data underlying mutation3D
In assembling a set of protein structures and models for use with mutation3D, we relied on the huge advances made in structural proteomics over the past decade. Alongside the explosion of genomic sequencing data, the availability of structural proteomic data, including crystal structures and homology models, has increased dramatically. In 2003, there were 25,864 crystal structures in the Protein Data Bank (Berman, 2000) (PDB), covering 6.7% of the human proteome. Now, with the number of entries in the PDB exceeding 100,000, we can visualize nearly 90% (with reasonable accuracy and coverage-see Supp. Figure S1 ) of the human proteome through a combination of experimentally-determined crystal structures and structural models based on shared structural elements among homologous proteins. mutation3D curates both crystal structures from the PDB and high-quality homology models from ModBase (Pieper, et al., 2011) to populate its repository of over 135,000 protein structures (Figure 2a ). This significant underpinning of structural proteomic data ensures that mutation3D is useful for large-scale sequencing projects, as nearly all DNA mutations of interest within coding regions will be mappable to 3D locations in protein structures.
Seamless access to large-scale somatic cancer mutation sets
Perhaps the richest large-scale source of missense mutation data derives from WGS studies of cancer patient cohorts. According to COSMIC, in the year 2003, 187 peer-reviewed articles were published reporting on average a single gene with protein-altering somatic mutations in tumor-normal sequencing studies. In 2012, 572 studies reporting an average of 144 mutated genes were published. With the growing ease of sequencing, the scientific community has largely embraced the wholesale sequencing of tumor samples, and an accompanying class of statistical methods to identify genes characterized by elevated mutation rates across large patient cohorts (Cancer Genome Atlas, 2012; Hodis, et al., 2012; Lawrence, et al., 2014; Lawrence, et al., 2013; Sjöblom, et al., 2006; Wood, et al., 2007) . These methods have been largely successful, and have led to the discovery of many genes previously not known to be involved in tumorigenesis. However, studying cancer at the level of whole genes ignores the fact that many genes and their protein products perform multiple cellular functions (pleiotropy). By incorporating available protein structures and models into cancer gene detection, we can harness the inherent structure-function relationship in proteins to identify more specific tumorigenic etiologies based on specific spatial disruptions that could become therapeutic targets.
The mutation3D web interface allows users to rapidly analyze pre-processed missense mutation data from the most recent build of COSMIC through intuitive web forms on the (Figure 2b ). Additionally, users may choose to tune the default clustering parameters (Supp. Note S3) and protein structural model set (Supp. Note S2) based on the types of evidence needed to support clusters for their specific application. A list of candidates, with links to 3D views of the mutations overlaid onto structural models ( Figure   2c ), are retrieved within seconds, even for the largest WGS studies in COSMIC.
mutation3D identifies well-validated gene candidates and plausible new targets
We ran mutation3D on large sets of known inherited disease and cancer mutations to demonstrate the power of clustering to reveal shared etiologies in the structural proteome.
Here, and in all following large-scale analyses, mutations associated with each distinct disease phenotype are considered separately from mutations associated with unrelated phenotypes so that a correspondence can be made between clusters in functionally relevant parts of protein structures and potential defects in molecular function that may cause one specific disease or type of cancer. We demonstrate the ability of mutation3D to distinguish functional from non-functional mutations in disease and to re-discover many known cancercausing genes as well as discovering several new putative targets. Parameters for all tests performed are available in Methods and in Supp. Table S4 .
mutation3D distinguishes disease mutations from common variants
To illustrate the efficacy of mutation3D in distinguishing functional from non-functional variants, we considered all proteins harboring at least 3 mutations associated with a single disease (according to HGMD) and all missense population variants (SNPs) from the ESP 6500 data set for this same set of proteins (see Methods for details). We were able to show that the resulting set of 8,869 disease-causing amino acid substitutions are more likely to be clustered by mutation3D than are 2,004 putatively benign substitutions arising from missense SNPs when considering only those mutations associated with a single disease at a time mixed together with SNPs in the same proteins (Figure 3a-b) . This trend is apparent irrespective of whether the protein structure set is confined to known PDB structures, homology models from ModBase, or a combination of the two.
This analysis illustrates mutation3D's ability to distinguish functional from nonfunctional variants when all functional variants share an associated phenotypic consequence.
Because it is often difficult to determine which cancer mutations are drivers and which are passengers, mutation3D's ability to distinguish functional disease mutations from nonfunctional SNPs serves as a proxy measure of its ability to separate functional driver mutations from a background of largely non-functional passenger mutations.
mutation3D identifies both new and well-known cancer genes
To confirm that mutation3D identifies plausible driver gene candidates in cancer (as judged by the existence of one or more clusters of substitutions in structures of their protein products), we computed statistically significant clusters from mutations in all WGS studies cataloged by COSMIC. First, we calculated the proportion of the identified cancer candidates that have been previously proposed as cancer drivers based on a combination of the Cancer Gene Census database (Futreal, et al., 2004) and the MutSig driver list (Lawrence, et al., 2014) . This is likely to be correlated with the lower bound of precision, or positive predictive value, of our method (see Methods). Figure 3c illustrates the calculated proportion values for all publications analyzed and for specific tissues within these studies, plotted over several cluster sizes. The results concur with our expectation that tighter mutation clusters should exhibit high precision for known cancer genes since substitutions in close physical proximity will be more likely than distant substitutions to be contained within the same interface domain or within the hydrophobic protein core. As expected, we also observe lower precision in the identification of genes involved in cancers of the skin, which are characterized by very high mutation rates (Alexandrov, et al., 2013) . By contrast, cancers of the breast are known to harbor driver mutations in a relatively small number of genes and contain a relatively low proportion of passenger mutations (Kan, et al., 2010) , thereby allowing mutation3D to precisely identify known cancer genes irrespective of cluster size.
To confirm that our statistical model yields plausible measures of cluster significance, we computed the statistical significance of clusters found in COSMIC WGS data. We find that our iterative bootstrapping model (See Methods) produces P-values that are highly correlated with the likelihood of a gene to be a known cancer genes (Figure 3d ). We repeated both this and the study in Figure 3c using the Cancer Gene Census and MutSig cancer gene list separately to define a list of known cancer genes. We find the relative observed trends remain the same, confirming the robustness of our analyses (Supp. Figure S2 ).
We also find that the somatic mutations within these clusters are predicted to be more deleterious by PolyPhen-2 when found in smaller, more specific clusters (Figure 3e ).
Furthermore, mutations within clusters are observed at much higher frequencies within WGS studies, suggesting they are likely to be driver mutations (Figure 3f ). Overall, these analyses suggest a tendency for functionally important mutations to form clusters in cancer patient cohorts, whereas less important passenger mutations are more likely to fall outside these clusters.
We next investigated whether mutation3D preferentially reports potential oncogenes or tumor suppressors. We find that of genes annotated in either class based on the Cancer Gene Census, there is not a significant difference in the likelihood mutation3D will find clusters within their protein products (Supp. Note S5, Supp. Figure S3 ). This suggests that mutation3D is equally robust in its ability to detect oncogenes and tumor suppressors.
Finally, we produced a list of the genes whose protein products most commonly exhibit clusters of mutations within the same set of COSMIC WGS publications. We find that mutation3D implicates many well-known cancer genes (TP53, KRAS, EGFR, BRAF, etc.) as well as some genes that are missing from the Cancer Gene Census (Figure 4a ). Visual inspection of the most significant clusters for each of these proposed genes demonstrates the power of 3D clustering (Figure 4b ). A list of all genes found in at least 4 studies across COSMIC is available in Supp. Table S5 .
Discussion
Researchers have already begun to acknowledge the added benefit of linear clustering approaches to the detection of driver mutations in two recently proposed methods (Lawrence, et al., 2014; Tamborero, et al., 2013) . However, these methods do not take into account the 3D positions of mutations within protein products, disregarding information available due to structure-function relationships in proteins. Two other recent methods (Ryslik, et al., 2012; Ryslik, et al., 2014) perform 1D clustering of mutations after a projection of 3D structural coordinates into 1D, potentially resulting in loss of information (Supp. Note S6, Supp. Figure   S4 ). Clustering methods have also been used to detect signatures of positive selection form a tight cluster in a crystal structure of GTPase KRas, whereas a substitution (E49K) only observed once in COSMIC (shown in blue), is likely to be a passenger mutation and falls outside the 3D mutation cluster even though it appears to be in close proximity in the linear model. 
